This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Xermelo
  • /
  • Telotristat Etiprate for Carcinoid Syndrome Therap...
Clinical trial

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Read time: 2 mins
Last updated:11th Mar 2014
Identifier: NCT02063659

The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
Actual Study Start Date: March 11, 2014
Actual Primary Completion Date: March 29, 2016
Actual Study Completion Date: March 29, 2016

- Experimental:
250 mg Telotristat Etiprate
- Experimental: 500 mg Telotristat Etiprate
- Placebo Comparator: Placebo

Related journal:
- Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Category Value
Date last updated at source 2018-02-26
Study type(s) Interventional
Expected enrolment 76
Study start date 2014-03-11
Estimated primary completion date 2016-03-29

View full details